MedWatch

Top picks in English

Novo Seeds invests millions in Belgian cancer company

Brussels-based biotech company Camel-IDS has raised EUR 37 million (USD 41.83 million) to continue the development of the phase I candidate against an especially aggressive form of breast cancer. Danish Novo Seeds is among the lead investors.

Discovery of RNA-degrading mechanism can open for new class of diabetes drugs

Researchers from University of Copenhagen have discovered exactly how inflammation hinders insulin production in patients with type 2 diabetes. According to one of the professors, the discovery could bring about a whole new class of diabetes drugs based on one of the most promising fields of biotechnology: RNA.

Former Eli Lilly and Sanofi exec to establish pain killer empire

Danish researcher Philip Just Larsen has conducted diabetes research for companies like Novo Nordisk, Sanofi and Eli Lilly. Now, he is CSO in German Grünenthal and aims to develop the future's pain killers and maybe even find a solution to the deadly opioid addiction.

Roche is Denmark's second best mid-sized workplace

Roche is the second best mid-sized workplace in Denmark 2018. This is according to an analysis from the consultancy firm Great Place to Work. And for the twelfth year in a row, the Danish unit of the drug group takes a place in top 5.

Headhunter: This man could be the next CEO of GN Hearing

Last week, CEO in GN Hearing, Anders Hedegaard, announced his resignation. The search for a new top manager for the Danish hearing aid group has begun, and Hedegaard's successor might very well come from one of the company's closest competitors. Headhunters especially point towards one candidate.

Novo Seeds on Galecto financing: Our biggest investment ever

Novo Seeds invests DKK 100 million more in Danish biotech company Galecto and becomes the principal shareholder - in every way a significant investment and according to Senior Partner, Stephan Christgau, the biggest so far in the venture fund's history.